FDA expands use of Xarelto to treat, reduce recurrence of blood clots
The US Food and Drug Administration today expanded the approved use of Xarelto (rivaroxaban) to include treating deep vein thrombosis (DVT) or pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE following initial treatment.
FDA Rejects Rivaroxaban for ACS
Following a close vote, a U.S. Food and Drug Administration panel has declined to recommend r ivaroxaban ( Xarelto ) to treat acute coronary syndrome.
Risk High During Temporary Anticoagulant Halts
Patients with certain types of atrial fibrillation, a common heart arrhythmia, are at a high risk of stroke and blood clots if they temporarily stop their blood thinning medication before surgery or permanently because of side effects.
Rivaroxaban for Treating Pulmonary Embolism
New oral blood thinner rivaroxaban ( Xarelto ) has been shown to be safer for treating a pulmonary embolism as compared to enoxaparin ( Lovenox ) injections, and was found to be just as effective.
FDA Approves Xarelto To Reduce Risk Of Blood Clots
On July 1, the U.S. Food and Drug Administration approved Xarelto ( rivaroxaban ) to reduce the risk of blood clots, deep vein thrombosis ( DVT ), and pulmonary embolism (PE) following knee or hip replacement surgery.